Intravenous immunoglobulin (IVIg), the first line therapy in GBS, significantly promoted both the expansion of CD4+CD25+Foxp3+ regulatory T cells (Tregs) and secretion of IL-10 and TGF-β1 [26]. The gene discussed is CD4; the disease is Guillain-Barre syndrome.